Peak Bio, Inc. Common Stock
PKBO
PKBO was delisted on the 9th of January, 2023.
36 hedge funds and large institutions have $34.3M invested in Peak Bio, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 0 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
20% more funds holding
Funds holding: 30 → 36 (+6)
3% more capital invested
Capital invested by funds: $33.4M → $34.3M (+$957K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$747K |
| 2 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$342K |
| 3 |
Walleye Capital
New York
|
+$215K |
| 4 |
CFIA
Cantor Fitzgerald Investment Advisors
New York
|
+$157K |
| 5 |
HIH
HRS Investment Holdings
New York
|
+$157K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KIM
Karpus Investment Management
Pittsford,
New York
|
-$166K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$59.7K |
| 3 |
Millennium Management
New York
|
-$59.2K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$6.55K |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$1.96K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Goldman Sachs
New York
| $235K | – | – | – |
|
|
27
Walleye Capital
New York
| $214K | +$215K | +22,000 | New |
|
|
CM
28
Crestline Management
Fort Worth,
Texas
| $204K | – | – | – |
|
|
RCM
29
Rivernorth Capital Management
West Palm Beach,
Florida
| $196K | – | – | – |
|
|
HIH
30
HRS Investment Holdings
New York
| $157K | +$157K | +16,034 | New |
|
31
Walleye Trading
New York
| $156K | +$157K | +16,000 | New |
|
|
CFIA
32
Cantor Fitzgerald Investment Advisors
New York
| $156K | +$157K | +16,034 | New |
|
|
RA
33
RiverPark Advisors
New York
| $132K | – | – | – |
|
|
OMC
34
Old Mission Capital
Chicago,
Illinois
| $128K | +$129K | +13,172 | New |
|
35
UBS Group
Zurich,
Switzerland
| $19K | +$4.89K | +500 | +33% |
|
|
TRCT
36
Tower Research Capital (TRC)
New York
| $1K | – | – | – |
|
PKBO Hedge Fund Activity: Q4 2021 in Review
36 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Peak Bio, Inc. Common Stock (PKBO) for Q4 2021, worth a combined $34.3M — up 2.9% from $33.4M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PKBO positions and 0 closed out — a net gain of 6 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $747K. The largest seller was Karpus Investment Management, cutting an estimated $166K.
- 36 institutional investors held Peak Bio, Inc. Common Stock (PKBO) as of Q4 2021, up from 30 in Q3 2021.
- Funds reported $34.3M of Peak Bio, Inc. Common Stock stock for Q4 2021, up 2.9% quarter-over-quarter.
- 6 funds opened new Peak Bio, Inc. Common Stock positions in Q4 2021 and 0 closed out, a net change of +6 holders.
- The largest Peak Bio, Inc. Common Stock buyer in Q4 2021 was D.E. Shaw & Co, an estimated $747K added.
- The largest Peak Bio, Inc. Common Stock seller in Q4 2021 was Karpus Investment Management, an estimated $166K sold.
Based on aggregated 13F filings for Q4 2021.